Form 4 for SLXN Silexion Therapeutics Corp
Accepted 2026-02-23 00:00:00 ET · period of report 2026-02-20 · accession 0001178913-26-000598 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-02-23 | 2026-02-20 | SLXN | Abramov Dror Yosef | Dir | A - Grant | $0.00 | +9,091 | 10.2K | +835% | $0 |
| D | 2026-02-23 | 2026-02-20 | SLXN | Abramov Dror Yosef | Dir | A - Grant | $0.00 | +10.7K | 10.7K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2026-02-20 | A | A | 9,091 | $0.00 | 10,180 | D | — | — | |
| 2 | Derivative | Stock Option (right to buy ordinary shares) | 2026-02-20 | A | A | 10,685 | $0.00 | 10,685 | D | $1.65 · 2027-02-12 to 2036-02-12 | 10,685 Ordinary Shares | (F3) The options reported in this row vest in their entirety on the one-year anniversary of, and expire on the ten-year anniversary of, the date of approval of their grant by the Issuer's board of directors. |